Study of NEO-201 in Solid Tumors Expansion Cohorts

计划入组 121 人 · 首次发布于 2018 年 3 月 26 日

RAPA-201 Therapy of Solid Tumors

计划入组 37 人 · 首次发布于 2021 年 12 月 3 日

A study to assess the safety and tolerability of next-generation neoantigen-selected Tumor-infiltrating Lymphocyte (TIL) therapy. NEXTGEN-TIL-ACT

计划入组 10 人 · 首次发布于 2024 年 10 月 21 日

solid tumors therapy

CLK3 inhibitor (oral, solid tumors), Biosplice Therapeutics

CLK2 inhibitor (oral, solid tumors), Biosplice Therapeutics

Solid Biosciences Inc.

United States

Yichang Humanwell Oral Solid Dosage Plant

China

BioLine Rx

Israel

Invikafusp Alfa Demonstrates Promising Activity in Immune Checkpoint Inhibitor-Resistant Solid Tumors

Singapore's PRL3-zumab Shows Promise in Phase II Trial for Treatment-Resistant Solid Tumors

Invikafusp Alfa Shows Promise in Checkpoint Inhibitor-Resistant Solid Tumors with High Disease Control Rates